Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0214)
Drug Name
Binimetinib
Synonyms
Binimetinib; Binimetinib (JAN/USAN); Binimetinib [USAN:INN]; MEK 162; MEK-162; MEK162; MEK162 (ARRY-162, ARRY-438162); MEK162(Binimetinib); Mektovi; Mektovi (TN); NVP-MEK162; SCHEMBL570088; 181R97MR71; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 606143-89-9; ARRY 162; ARRY 438162; ARRY-162; ARRY-438162; Binimetinib (MEK162, ARRY-162, ARRY-438162); C17H15BrF2N4O3; CHEMBL3187723; GTPL7921; MLS006011180; UNII-181R97MR71
Indication Melanoma [ICD11: 2C30] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 441.2 Topological Polar Surface Area 88.4
Heavy Atom Count 27 Rotatable Bond Count 6
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
10288191
PubChem SID
15294150 ; 22663761 ; 35560186 ; 76385017 ; 136920431 ; 139722085 ; 152256088 ; 152258645 ; 160647480 ; 162011797 ; 162108908 ; 163750757 ; 164042001 ; 172919200 ; 174006430 ; 174529974 ; 185990487 ; 198988096 ; 223386768 ; 223705205 ; 225848212 ; 226876700 ; 242590736 ; 243963093 ; 249565604 ; 252215762 ; 252450328 ; 252554049
ChEBI ID
CHEBI:145371
CAS Number
606143-89-9
TTD Drug ID
D0C4LF
Formula
C17H15BrF2N4O3
Canonical SMILES
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
InChI
1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
InChIKey
ACWZRVQXLIRSDF-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
1,4-Diiminoquinone intermediate DM001422 N. A. Oxidation - Two-Electron Oxidation 1 [3]
GSH adduct DM001423 N. A. Unclear 2 [3]
Binimetinib metabolite M1 DM001424 N. A. Unclear 3 [3]
Binimetinib metabolite M4 DM001427 N. A. Unclear 3 [3]
Binimetinib metabolite M2 DM001425 N. A. Unclear 4 [3]
Binimetinib metabolite M3 DM001426
139593402
Unclear 4 [3]
Binimetinib metabolite M5 DM001428 N. A. Unclear 4 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000372 Binimetinib 1,4-Diiminoquinone intermediate Oxidation - Two-Electron Oxidation CYP2D6 ... [3]
MR000366 1,4-Diiminoquinone intermediate GSH adduct Unclear Unclear [3]
MR000367 GSH adduct Binimetinib metabolite M1 Unclear Unclear [3]
MR000368 GSH adduct Binimetinib metabolite M4 Unclear Unclear [3]
MR000369 Binimetinib metabolite M1 Binimetinib metabolite M2 Unclear Unclear [3]
MR000370 Binimetinib metabolite M1 Binimetinib metabolite M3 Unclear Unclear [3]
MR000371 Binimetinib metabolite M4 Binimetinib metabolite M5 Unclear Unclear [3]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[3]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Homo sapiens
UD11_HUMAN
2.4.1.17
[4]
References
1 Binimetinib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
3 Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2 Chem Res Toxicol. 2021 Apr 19;34(4):1169-1174. doi: 10.1021/acs.chemrestox.1c00036.
4 Binimetinib - European Medicines Agency - European Union

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.